Clinical Trial Update: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Verastem is evaluating the KRAS G12D-mutated cancer drug VS-7375 in a Phase 1/2 study across several solid tumors, including pancreatic ductal adenocarcinoma, n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• VS-7375

Snippet

Sponsor: Verastem, Inc. | Conditions: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING